UroCCR Database: French Research Network for Kidney Cancer -UroCCR
UroCCR
1 other identifier
observational
30,000
3 countries
3
Brief Summary
Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Funded by the French National Cancer Institute (INCa), UroCCR prospectively collects comprehensive real-world data on patient care and disease evolution, while systematically linking these records with annotated biological samples (plasma, urine, and both healthy and tumour tissues). For each case, more than one thousand variables may be recorded, covering clinical, imaging, and patient-reported information. More than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels. By combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2011
Longer than P75 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2011
CompletedFirst Submitted
Initial submission to the registry
July 12, 2016
CompletedFirst Posted
Study publicly available on registry
September 26, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2040
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2040
September 17, 2025
September 1, 2025
29 years
July 12, 2016
September 10, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
Operative time, ,
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
Blood loss
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
Clinical scores
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Secondary Outcomes (8)
Dosage of creatininemia to assess the renal function after surgery
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Dosage of MDRD GFR to assess the renal function after surgery
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
- +3 more secondary outcomes
Study Arms (1)
Patients
Adult patients with kidney cancer
Interventions
Eligibility Criteria
Patients with Kidney cancer
You may qualify if:
- Adult patient with kidney cancer
- Patient with no opposition to collection of its data for the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (58)
Hopital Universitaire de Bruxelles
Brussels, Belgium
CHU Angers
Angers, 49100, France
CHU Bordeaux
Bordeaux, 33076, France
Clinique TIVOLI-DUCOS
Bordeaux, France
Polyclinique Médipôle Saint-Roch_Cabestany
Cabestany, France
CHU Caen
Caen, France
CHU de Clermont-Ferrand
Clermont-Ferrand, France
Ch Sud Francilien
Corbeil-Essonnes, France
CHU Henri Mondor - APHP
Créteil, 94010, France
CHU de Dijon et CLCC Dijon
Dijon, France
CH du Sud Seine et Marne
Fontainebleau, France
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon, France
CHU Grenoble
La Tronche, 38700, France
Pôle Santé Sud
Le Mans, France
CH Libourne
Libourne, France
CHRU Lille - Centre Oscar Lambret
Lille, 59037, France
Hôpital privé La Louvière
Lille, France
CHU Limoges
Limoges, 87042, France
HCL Lyon
Lyon, 69002, France
APH Marseille
Marseille, France
Institut Paoli-Calmette
Marseille, France
Centre Hospitalier d' Annecy Genevois
Metz, France
CH Mont de Marsan
Mont-de-Marsan, France
Clinique du Pont de Chaume
Montauban, France
CHRU de Nancy
Nancy, France
CHU de Nantes
Nantes, France
CHU de Nice
Nice, France
Clinique Saint George
Nice, France
CHU de Nîmes
Nîmes, France
CHU d'Orléans
Orléans, France
CHU Kremlin Bicêtre - APHP
Paris, 75013, France
CH St Joseph
Paris, 75014, France
Hôpital Européen Georges Pompidou - APHP
Paris, 75015, France
CHU Tenon - APHP
Paris, France
Hôpital Bichat -APHP
Paris, France
Hôpital Cochin Port-Royal - APHP
Paris, France
Hôpital Pitié Salpétrière - APHP
Paris, France
Institut Mutualiste Montsouris
Paris, France
Polyclinique Francheville
Périgueux, France
Hôpital privé des Côtes d'Armor
Plérin, France
CHU Poitiers
Poitiers, France
Hôpital privé Claude Galien
Quincy-sous-Sénart, France
Clinique La Croix Du Sud
Quint-Fonsegrives, France
CHU Reims
Reims, France
CHU Rennes - Centre Eugène Marquis
Rennes, 35000, France
CHU Rouen
Rouen, 76031, France
CHU St-Etienne
Saint-Etienne, France
Clinique Santé Atlantique de Nantes
Saint-Herblain, France
Clinique Urologique Nantes Atlantis
Saint-Herblain, France
Clinique Belledonne
Saint-Martin-d'Hères, France
CHU Strasbourg
Strasbourg, 67000, France
ICANS
Strasbourg, France
CHU Toulouse - Centre Claudius Régaud
Toulouse, 31059, France
Clinique Pasteur
Toulouse, France
CHRU Tours
Tours, France
Institut de Cancérologie lorraine
Vandœuvre-lès-Nancy, France
Centre Hospitalier de Kourou
Kourou, French Guiana
CHU Bellepierre
Saint-Denis, Reunion
Related Publications (4)
Binzaqr S, Kryza D, Giraudet AL, Bernhard JC, Gross-Goupil M, Yacoub M, Margue G, Hindie E, Morgat C. Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study). EJNMMI Res. 2025 Apr 9;15(1):38. doi: 10.1186/s13550-025-01232-8.
PMID: 40205264DERIVEDIngels A, Bensalah K, Beauval JB, Paparel P, Roupret M, Lang H, Nouhaud FX, Henon F, Bruyere F, Audenet F, Lebacle C, Baumert H, Long JA, Tambwe R, Charles T, Xylinas E, Waeckel T, Michiels C, Asselineau J, Benard A, Margue G, Boissier R, Bigot P, Bernhard JC; Comite Cancer de l'Association Francaise d'Urologie (CCAFU). Comparison of open and robotic-assisted partial nephrectomy approaches using multicentric data (UroCCR-47 study). Sci Rep. 2022 Nov 8;12(1):18981. doi: 10.1038/s41598-022-22912-8.
PMID: 36347900DERIVEDMorrone A, Bentellis I, Bernhard JC, Bensalah K, Champy C, Bruyere F, Doumerc N, Olivier J, Audenet F, Parier B, Brenier M, Long JA, Nouhaud FX, Branger N, Lang H, Charles T, Xylinas E, Waeckel T, Gomez F, Boissier R, Rouget B, Shaikh A, Chevallier D, Ambrosetti D, Durand M. Positive surgical margin's impact on short-term oncological prognosis after robot-assisted partial nephrectomy (MARGINS study: UroCCR no 96). Sci Rep. 2022 Oct 31;12(1):18342. doi: 10.1038/s41598-022-23146-4.
PMID: 36316438DERIVEDBrehier G, Bouvier A, Besnier L, Willoteaux S, Nedelcu C, Culty T, Aube C, Bigot P. Renal function after partial nephrectomy following intra-arterial embolization of renal tumors. Sci Rep. 2020 Dec 7;10(1):21352. doi: 10.1038/s41598-020-78461-5.
PMID: 33288819DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jean-Christophe BERNHARD, PHU
University Hospital, Bordeaux
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 12, 2016
First Posted
September 26, 2017
Study Start
December 1, 2011
Primary Completion (Estimated)
December 1, 2040
Study Completion (Estimated)
December 1, 2040
Last Updated
September 17, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share